Circassia Pharmaceuticals PLC Receives New Coverage from Analysts at Canaccord Genuity (CIR)
Research analysts at Canaccord Genuity assumed coverage on shares of Circassia Pharmaceuticals PLC (LON:CIR) in a report released on Tuesday, American Banking and Market News reports. The firm set a “buy” rating and a GBX 341 ($5.73) price target on the stock.
Shares of Circassia Pharmaceuticals PLC (LON:CIR) opened at 294.23 on Tuesday. Circassia Pharmaceuticals PLC has a 52-week low of GBX 268.00 and a 52-week high of GBX 316.75. The stock has a 50-day moving average of GBX 300.4 and a 200-day moving average of GBX 300.4.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.